SEC Form 4 · accession 0001209191-16-091465
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — COO
Period of report
Jan 12, 2016
Accepted (ET)
Jan 14, 2016 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 12, 2016 | M | 542 | $18.89 | A | 27,970 | D | |
| Common Stock | Jan 12, 2016 | M | 3,458 | $18.89 | A | 31,428 | D | |
| Common StockF1,F2,F3,F4 | Jan 12, 2016 | S | 542 | $30.6452 | D | 30,886 | D | |
| Common StockF1,F3,F5,F4 | Jan 12, 2016 | S | 3,458 | $31.8569 | D | 27,428 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $18.89 | Jan 12, 2016 | M | 542 | D | — | Nov 30, 2016 | Common Stock | 542 | 31,458 | D |
| Employee Stock Option (right to buy)F6 | $18.89 | Jan 12, 2016 | M | 3,458 | D | — | Nov 30, 2016 | Common Stock | 3,458 | 28,000 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 24, 2014.
- F2Represents weighted average sale price. Actual sale prices ranged from $30.31 to $30.95.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Includes an aggregate of 16,201 shares of common stock issuable pursuant to previously reported restricted stock units and performance-based vesting restricted stock units awards that have not vested.
- F5Represents weighted average sale price. Actual sale prices ranged from $31.39 to $32.14.
- F6The option became exercisable as to 25% of the shares on November 30, 2007, and became exercisable as to 1/48th of the shares each full month thereafter.